Consolidated revenue for Q3FY22 was up 17.1% YoY to Rs. 2,174cr (+18.1% QoQ), driven by a strong performance across all business segments. Biggest contributor to the revenue growth was the Biosimilars business. Biocon Biologics Ltd. recorded revenue of Rs. 981cr, a growth of 27.6% YoY (+32.2% QoQ) helped by robust demand across products and geographies and the launch of 351(k) biosimilar Insulin Glargine in the *over or under performance to benchmark index...